//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts









Loading...
Check how this work identifies the enhanced vulnerability of cyclin E-overexpressing TNBC cells to CDC7 kinase inhibition and substantial synergy when combined with CDK8 inhibition.
Check how their findings demonstrate that PRMT6-dependent EZH2 methylation plays an important role in driving breast tumour growth, revealing a new epigenetic mechanism of PRMT6 in the breast cancer and highlighting PRMT6 inhibition as a potentially therapeutic strategy.
Check how their findings reveal the underlying mechanism of PLEKHA4 in regulating glioblastoma cell glycolysis and indicate a potential new target for GBM treatment.
Check how this study shows that while prostasin deficiency does not affect primary tumor growth, it results in a significantly increased of metastasis due to the crucial role of fibronectin in tight junctions.
Check how this study uncovers a mechanism whereby FBP1 can be regulated by a protein O-GlcNAcylation-polyubiquitination axis, paving the way to cancer cell metabolic reprogramming and tumour progression in pancreatic cancer.
“Cyclin E modulates vulnerability to CDC7 kinase inhibition” 🔵 Agnieszka K. Witkiewicz‘s latest research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...